

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5491124

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YU-CHONG TAI	09/29/2017
COLIN A. COOK	09/29/2017
RECEIVING PARTY DATA	
Name:	CALIFORNIA INSTITUTE OF TECHNOLOGY
Street Address:	1200 EAST CALIFORNIA BLVD.
City:	PASADENA
State/Country:	CALIFORNIA
Postal Code:	91125
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15722751
PCT Number:	US2017054746
CORRESPONDENCE DATA	
Fax Number:	(925)472-8895
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9254725000
Email:	sarnold@kilpatricktownsend.com
Correspondent Name:	SYLVIA ARNOLD
Address Line 1:	KILPATRICK TOWNSEND & STOCKTON LLP/CALTECH
Address Line 2:	1100 PEACHTREE STREET, SUITE 2800
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	086544-106221-020610US
NAME OF SUBMITTER:	SYLVIA ARNOLD
SIGNATURE:	/Sylvia E. Arnold/
DATE SIGNED:	04/24/2019
Total Attachments: 2	
source=2019-04-24_ASN_086544-1062210-020610US#page1.tif	
source=2019-04-24_ASN_086544-1062210-020610US#page2.tif	

Attorney Docket No. 086544-1062209-020600US
Attorney Docket No. 086544-1062210-020610US
Attorney Docket No. 086544-1062211-020610PC

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in utility (provisional and non-provisional), PCT, or design patent application as follows:

US Provisional Appln. No. 62/403569 filed October 3, 2016, Attorney Docket No. 086544-1062209-020600US, entitled: "IMPLANTABLE RADIOLUMINESCENT PHOTOTHERAPY DEVICE";

US Non-Provisional Appln. No. 15/722,751 filed on October 2, 2017, Attorney Docket No. 086544-1062210-020610US, entitled: "RADIOLUMINESCENT EYE PHOTOTHERAPY DEVICE"; and

PCT Patent Appln. No. PCT/US2017/054746 filed on October 2, 2017, Attorney Docket No. 086544-1062211-020610PC, entitled: "RADIOLUMINESCENT EYE PHOTOTHERAPY DEVICE".

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we [I] acknowledge, we [I]:

- I. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to California Institute of Technology, a other entity of the State of California having a principal place of business at 1200 E California Blvd, Pasadena, CA 91125 ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts,

ASSIGNMENT

Attorney Docket No. 086544-1062209-020600US; Attorney Docket No. 086544-1062210-020610US; Attorney Docket No. 086544-1062211-020610PC

Page 2 of 2

continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

(e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us [me], as well as our [my] heirs, legal representatives, and assigns.
5. Promise and affirm that we [I] have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our [my] signatures [signature].

Signature: _____
Yu-Chong Tai

Date: 9/29/2017

Signature: _____
Colin A. Cook

Date: 29-Sep-2017